Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Caelyx

- PMLiVE

Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer

Drug approved in combination with Merck's KGaA's Erbitux

- PMLiVE

NICE launches consultation on its methods of drug evaluation

Public consultation launched on Friday 6 November

- PMLiVE

NICE – but not enough

Why evidence is better than assumption when executing commercial strategy

- PMLiVE

NICE recommends Roche’s Polivy for B-cell lymphoma

Cost-effectiveness agency approves drug following initial rejection earlier this year

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

- PMLiVE

Tecentriq misses the mark in advanced ovarian cancer

PD-L1 inhibitor failed to improved progression-free survival

- PMLiVE

NICE looks internally for new chief executive

Deputy chief exec Gillian Leng is set to take the helm

- PMLiVE

Celgene’s Revlimid scores NICE approval in follicular lymphoma

New ‘chemotherapy-free’ treatment for patients with limited options

- PMLiVE

IMV preps pivotal trials for ovarian cancer T cell therapy

Drug stabilised disease in 79% of 19 evaluable patients

- PMLiVE

FDA accepts review to broaden GSK’s Zejula label

Seeks approval in advanced ‘all-comer’ ovarian cancer population

- PMLiVE

NICE plans to widen the net for data it uses in guidance

Plans to include electronic health records and real-world evidence

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links